|
=====================================
THE MAGNIFIER - Electronic Newsletter
Issue #15, December 28, 2002
Produced by:
Macular Degeneration Foundation, Inc.
P.O. Box 531313 Henderson, NV 89053
http://www.eyesight.org
CONTENTS:
1] HARVARD RESEARCH PROJECT
2] MICROCURRENT STIMULATION (Preview)
=====================================
HARVARD ANGIOGENESIS INHIBITOR RESEARCH PROJECT
Macular Degeneration Foundation has begun to contribute research funds to Harvard Medical School. A team of
scientists at Harvard, including our Dr. Robert J. D'Amato (the Foundation's Director of Clinical Research) has identified Cytochalasin E, an angiogenesis inhibitor.
Angiogenesis is the formation or growth of new blood
vessels. In the most severe form of age-related macular degeneration (known as "wet" ARMD) abnormal angiogenesis occurs under the retina resulting in irreversible loss of vision. The loss of vision is due to scarring of
the retina secondary to the bleeding from the new blood vessels. The Harvard researchers propose that Cytochalasin E and analogs may be useful for the treatment of angiogenesis-dependent diseases like the "wet" form
of macular degeneration.
The following link will load a PDF document (Requires Adobe Reader). It provides technical background information published in March of 2000. An encouraging update is pending and we will
publish it both here and on our web site (www.eyesight.org) as soon as it becomes available.
The Macular Degeneration Foundation is very careful about the placement of research funds. While they cannot guarantee results,
this work by the Department of Surgical Research and Ophthamology, Children's Hospital, Harvard Medical School, Boston, MA is definitely a worthy cause. We ask readers of this newsletter to consider a donation of any size
sent to:
MACULAR DEGENERATION RESEARCH FUND, P.O. BOX 531313, HENDERSON, NEVADA 89053
http://www.eyesight.org/Research/Research-Cytochalasin_E/cytoE.pdf
AOL Users: <a
href="http://www.eyesight.org/Research/Research-Cytochalasin_E/cytoE.pdf">ATP Research</a>
THANK YOU.
=====================================
MICROCURRENT STIMULATION
Microcurrent stimulation has been used by mainstream medicine for years. However, its use as a treatment for macular degeneration has been limited to the fringes of medicine. The Foundation decided to study all available science
and anecdotal evidence. We were very encouraged by what we learned and will be making an annoucement in the near future regarding how people with certain forms of macular degeneration may acquire a microcurrent stimulator for
personal use.
=============================
The MAGNIFIER is sent without charge. Contributions are appreciated and may be sent in care of the Macular Degeneration Research Fund, P.O. Box 531313,
Henderson, NV 89053
=============================
Subscribers who wish to cancel their subscription or change their email address may visit: http://www.eyesight.org/Newsletter/newsletter.html .
=============================
=============================
|
|
